About Interferon lambda receptor 1
Interferon lambda receptor 1 (IFNLR1) is a protein
from Homo sapiens identified by UniProt accession
Q8IU57, 520 residues long.
MolForge cross-references it against 0 known binders and
105 disease associations.
Target properties
| Protein name | Interferon lambda receptor 1 |
| UniProt accession | Q8IU57 |
| Gene | IFNLR1 |
| Organism | Homo sapiens |
| Length | 520 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (105)
Diseases linked to this target (Open Targets).
- hepatitis C virus infection · score 0.39
- psoriasis · score 0.37
- type 2 diabetes mellitus · score 0.32
- COVID-19 · score 0.30
- hepatitis D virus infection · score 0.29
- chronic hepatitis C virus infection · score 0.28
- ankylosing spondylitis · score 0.25
- Crohn's disease · score 0.25
- ulcerative colitis · score 0.25
- sclerosing cholangitis · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IU57-F1 | alphafold | PREDICTED | 64.23 | — |
Amino-acid sequence (520 residues)
MAGPERWGPL LLCLLQAAPG RPRLAPPQNV TLLSQNFSVY LTWLPGLGNP QDVTYFVAYQ SSPTRRRWRE VEECAGTKEL LCSMMCLKKQ DLYNKFKGRV RTVSPSSKSP WVESEYLDYL FEVEPAPPVL VLTQTEEILS ANATYQLPPC MPPLDLKYEV AFWKEGAGNK TLFPVTPHGQ PVQITLQPAA SEHHCLSART IYTFSVPKYS KFSKPTCFLL EVPEANWAFL VLPSLLILLL VIAAGGVIWK TLMGNPWFQR AKMPRALDFS GHTHPVATFQ PSRPESVNDL FLCPQKELTR GVRPTPRVRA PATQQTRWKK DLAEDEEEED EEDTEDGVSF QPYIEPPSFL GQEHQAPGHS EAGGVDSGRP RAPLVPSEGS SAWDSSDRSW ASTVDSSWDR AGSSGYLAEK GPGQGPGGDG HQESLPPPEF SKDSGFLEEL PEDNLSSWAT WGTLPPEPNL VPGGPPVSLQ TLTFCWESSP EEEEEARESE IEDSDAGSWG AESTQRTEDR GRTLGHYMAR
Explore Interferon lambda receptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets